Pular para o conteúdo
Menu
Mix Vale

Artificial intelligence cuts 12% of interval cancers and detects aggressive breast tumors earlier

Maria
Por 4 min de leitura
Compartilhe
Câncer de mama, atendimento médico, paciente
Foto: Câncer de mama, atendimento médico, paciente -Foto: Choreograph/ Istockphoto.com

Mammographic screening supported by artificial intelligence recorded a 12% reduction in interval cancers in a randomized study carried out at Suécia. The MASAI trial, coordinated by Lund University, involved more than 100 thousand women and demonstrated greater sensitivity in identifying tumors, especially the most aggressive ones. The findings indicate that the technology helps in early detection without compromising the specificity of the exams.

Publicidade

The application of AI occurred in regular mammographic screening programs in the European country. Pesquisadores compared the method with traditional double reading by radiologists and observed consistent benefits across different age groups and breast densities.

Interval cancers arise between rounds of exams and have more unfavorable characteristics. The decrease in these cases represents significant progress for public health programs.

Publicidade
  • 12% reduction in overall interval cancers.
  • 16% fewer invasive tumors detected late.
  • 21% fewer large cases (T2+).
  • 27% fewer non-luminal A subtypes, considered aggressive.

How technology works in screening

Artificial intelligence analyzes mammogram images and assigns a risk score on a scale of 1 to 10. Exames classified as low risk receive a single reading by a radiologist, while those at higher risk undergo double assessment.

This stratification maintains diagnostic accuracy and optimizes clinical workflow. The system highlights suspicious regions in the images to support medical decisions.

Researchers observed sensitivity of 80.5% in the AI ​​group, compared to 73.8% in the control group. Specificity remained at 98.5% in both groups.

Main results of the MASAI trial

The study followed women with a median age of approximately 54 years. The AI ​​intervention reduced the exam reading burden by 44% for radiologists.

Tumors identified early were smaller in size and lacked lymph node involvement in most cases. Esses factors are directly associated with better survival rates.

Publicidade

Detection occurred at the screening stage in 81% of cases with AI, compared to 74% with the conventional method.

Benefits observed in clinical practice

Professionals reported greater confidence in technologically supported analyses. The tool easily integrates with existing hospital IT systems.

Swedish regions have already adopted the model in their daily routine. Implementation only requires software compatible with digital mammography equipment.

Radiologists maintain a central role in the process. Pacientes express a preference for human assessment combined with technology.

The trial recorded 82 interval cancers in the intervention group versus 93 in the control group. The difference reinforces the effectiveness of the hybrid approach.

outubro rosa mulheres
Mama Cancer – AndrewLozovyi/depositphotos.com

Application to different patient profiles

The superiority of sensitivity remained consistent regardless of breast density. Mulheres with dense breasts especially benefit from automated analysis.

Similar results appeared across varying age groups. The performance was valid for invasive cancers, but did not differ significantly in in situ cases.

Workload reduction and operational efficiency

Radiologists face increasing volume of exams in population-based programs. AI alleviates this demand without increasing false positive rates.

False positives generate anxiety and unnecessary procedures in patients. The balance achieved in the study avoids this additional risk.

The reduced load allows for greater focus on complex cases. Profissionais save time for multidisciplinary discussions.

Global expansion potential

European countries are evaluating similar implementation in public health systems. Technology adapts to contexts with a shortage of specialists.

Breast cancer records millions of new cases annually around the world. Early Detecção raises cure rates above 90% in early stages.

Additional studies confirm positive trends. Pesquisas retrospectives have already indicated superior AI accuracy in image analysis.

Organized tracking programs benefit directly. Gradual integration preserves quality of care.

Limitations and future perspectives

The trial emphasizes the need for constant human supervision. Pacientes value interaction with health professionals.

Continuous algorithm training requires diverse data. Atualizações guarantee performance in heterogeneous populations.

Additional research evaluates impact on long-term mortality. Prolonged Seguimento will clarify definitive clinical benefits.

The combination of AI and medical expertise represents a promising model. Avanços Technological technologies continue to improve screening tools.

The MASAI study sets the benchmark for future trials. Resultados encourage responsible adoption of innovation.

Notícias relacionadas